Welcome to our dedicated page for Oric Pharmaceuticals SEC filings (Ticker: ORIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ORIC Pharmaceuticals, Inc. filings document a Nasdaq-listed clinical-stage oncology company focused on therapeutic resistance in cancer. Its 8-K reports furnish financial results and operational updates, clinical presentation materials for rinzimetostat (ORIC-944) and enozertinib (ORIC-114), and Regulation FD investor presentation slides.
Other disclosures cover ORIC's common stock, shelf registration and at-the-market share sales, prospectus supplement activity, emerging growth company status, and annual meeting proxy matters. The proxy record addresses stockholder voting, board governance, compensation oversight, and equity incentive arrangements, including inducement grants under Nasdaq listing rules.
Oric Pharmaceuticals director Richard A. Heyman exercised stock options to acquire 3,500 shares of common stock at $1.6000 per share and on July 24, 2026 sold a total of 13,100 common shares at $12.0200 per share, including 6,100 shares held through RAHD Capital, LLC. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Heyman and RAHD Capital, LLC. After the option exercise, 30,200 options remained outstanding and RAHD Capital, LLC held 206,672 shares over which he has voting and investment power.
Oric Pharmaceuticals director Richard A. Heyman, through an associated entity, reported a small insider sale of Oric Pharmaceuticals, Inc. common stock.
RAHD Capital, LLC, an entity for which Heyman has voting and investment power, sold 300 shares of common stock at $12.00 per share in an open-market transaction on July 6, 2026, executed under a pre-arranged Rule 10b5-1 trading plan. After this sale, RAHD Capital, LLC held 212,772 shares indirectly, while Heyman also reported a separate direct holding entry showing 41,800 shares owned directly.
ORIC Pharmaceuticals filed a Form 144 notice disclosing a proposed sale of Common stock. The filing lists 7,000 Common shares associated with J.P. Morgan Securities LLC and records two stock option exercises of 3,500 shares each dated 08/25/2016 and 07/06/2026. The filing names Nasdaq and includes identifying numbers shown in the excerpt.
ORIC Pharmaceuticals, Inc. reported results of its annual stockholder meeting and an update to its 2020 Equity Incentive Plan. Stockholders approved an amended and restated plan that changes how many shares can be added each year and clarifies limits on incentive stock options.
The plan’s annual “evergreen” increase was reduced from 5% to 4% of outstanding common shares while removing a prior 2,656,500-share annual cap, and it now caps shares issuable via incentive stock options at 10,000,000, subject to the overall share reserve. The amended plan also eliminates the administrator’s ability to run exchange or repricing programs for outstanding awards or allow transfers of awards to third parties.
At the meeting, held on June 18, 2026, stockholders elected two Class III directors, ratified KPMG LLP as auditor for the year ending December 31, 2026, approved executive compensation on an advisory basis, and chose to hold future advisory votes on executive pay every year. Of 103,517,562 shares outstanding as of April 20, 2026, 94,571,281 were represented, reflecting 91.36% participation.
Oric Pharmaceuticals, Inc. Schedule 13G/A reports that Viking Global Investors and affiliated reporting persons beneficially own 8,264,607 shares of Common Stock, representing 7.8% of the class. The filing states 103,486,412 shares outstanding as of March 31, 2026 and that the reporting persons hold rights to purchase 2,440,074 shares upon exercise of pre-funded warrants. The amendment notes that David C. Ott retired effective March 31, 2026 and was removed as a reporting person. The disclosure cites Rule 13d-3 for beneficial ownership attribution and lists the related Viking entities and principals with shared voting and dispositive power over the reported shares.
ORIC Pharmaceuticals ownership update: A group led by Venrock Healthcare affiliates reports beneficial ownership of 4,319,765 shares of ORIC common stock, equal to 4.2% of the class. The percentage is calculated using 103,486,412 shares outstanding as of March 31, 2026.
The filing names the Reporting Persons (Venrock Healthcare Capital Partners III, VHCP Co-Investment Holdings III, Venrock Healthcare Capital Partners EG, VHCP Management III, VHCP Management EG, Nimish Shah and Bong Koh) and states shared voting and dispositive power over the reported shares. Ownership figures are shown as of March 31, 2026.
Oric Pharmaceuticals filed an Amendment No. 1 to a Schedule 13G/A reporting that Point72-affiliated filers hold 0% of the class. The cover-page figures are stated as of the close of business on March 31, 2026. The amendment lists Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen as reporting persons and provides a principal business address.
ORIC Pharmaceuticals reported that T. Rowe Price Associates, Inc. beneficially owned 5,387,783 shares of Common Stock, representing 5.4% of the class as of 03/31/2026. The filing lists sole voting power of 5,382,293 shares and sole dispositive power of 5,387,783. The filer includes a written statement denying beneficial ownership.
Pfizer Inc. reports beneficial ownership of 3,442,940 shares of ORIC Pharmaceuticals common stock, representing 3.3% of the outstanding class. The percent is calculated on 103,517,562 shares outstanding as of April 27, 2026, as reported on the cover of ORIC's Form 10‑Q for the quarter ended March 31, 2026.
The filing is a Schedule 13G/A amendment signed by Madelyn D. Purcell on behalf of Pfizer, listing Pfizer's sole voting and dispositive power over the reported shares and providing Pfizer's Delaware status and business address.